These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 36879087)

  • 1. The Efficacy and Safety of Gefapixant in a Phase 3b Trial of Patients with Recent-Onset Chronic Cough.
    McGarvey L; Sher M; Shvarts YG; Lu S; Wu WC; Xu P; Schelfhout J; La Rosa C; Nguyen AM; Reyfman PA; Afzal AS
    Lung; 2023 Apr; 201(2):111-118. PubMed ID: 36879087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of gefapixant, a P2X
    McGarvey LP; Birring SS; Morice AH; Dicpinigaitis PV; Pavord ID; Schelfhout J; Nguyen AM; Li Q; Tzontcheva A; Iskold B; Green SA; Rosa C; Muccino DR; Smith JA;
    Lancet; 2022 Mar; 399(10328):909-923. PubMed ID: 35248186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 3, randomized, double-blind, clinical study to evaluate the long-term safety and efficacy of gefapixant in Japanese adult participants with refractory or unexplained chronic cough.
    Niimi A; Sagara H; Kikuchi M; Arano I; Sato A; Shirakawa M; La Rosa C; Muccino D
    Allergol Int; 2022 Oct; 71(4):498-504. PubMed ID: 35752582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial.
    Smith JA; Kitt MM; Morice AH; Birring SS; McGarvey LP; Sher MR; Li YP; Wu WC; Xu ZJ; Muccino DR; Ford AP;
    Lancet Respir Med; 2020 Aug; 8(8):775-785. PubMed ID: 32109425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Tolerability of Gefapixant for Treatment of Refractory or Unexplained Chronic Cough: A Systematic Review and Dose-Response Meta-Analysis.
    Kum E; Patel M; Diab N; Wahab M; Zeraatkar D; Chu DK; O'Byrne PM; Guyatt GH; Satia I
    JAMA; 2023 Oct; 330(14):1359-1369. PubMed ID: 37694849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvements in Objective and Subjective Measures of Chronic Cough with Gefapixant: A Pooled Phase 3 Efficacy Analysis of Predefined Subgroups.
    Smith JA; Birring SS; Dicpinigaitis PV; McGarvey LP; Morice AH; Pavord ID; Satia I; Green S; Iskold B; La Rosa C; Li Q; Martin Nguyen A; Schelfhout J; Muccino D
    Lung; 2022 Aug; 200(4):423-429. PubMed ID: 35895098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of 3 Weeks of Orally Administered Gefapixant in Healthy Younger and Older Adults.
    Nussbaum J; Hussain A; Ford A; Butera P; Kitt M; Smith S; Stoch A; Iwamoto M
    Lung; 2022 Jun; 200(3):315-323. PubMed ID: 35670873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of gefapixant, a P2X3 antagonist, on cough reflex sensitivity: a randomised placebo-controlled study.
    Morice AH; Kitt MM; Ford AP; Tershakovec AM; Wu WC; Brindle K; Thompson R; Thackray-Nocera S; Wright C
    Eur Respir J; 2019 Jul; 54(1):. PubMed ID: 31023843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with the P2X3-Receptor Antagonist Gefapixant for Acute Cough in Induced Viral Upper Respiratory Tract Infection: A Phase 2a, Randomized, Placebo-Controlled Trial.
    Smith JA; Kitt MM; Bell A; Noulin N; Tzontcheva A; Seng MM; Lu S
    Pulm Ther; 2022 Sep; 8(3):297-310. PubMed ID: 35969360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of gefapixant in women with chronic cough and cough-induced stress urinary incontinence: a phase 3b, randomised, multicentre, double-blind, placebo-controlled trial.
    Birring SS; Cardozo L; Dmochowski R; Dicpinigaitis P; Afzal A; La Rosa C; Lu S; Nguyen AM; Yao R; Reyfman PA
    Lancet Respir Med; 2024 Nov; 12(11):855-864. PubMed ID: 39222649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Persistent Cough in Subjects with Idiopathic Pulmonary Fibrosis (IPF) with Gefapixant, a P2X3 Antagonist, in a Randomized, Placebo-Controlled Clinical Trial.
    Martinez FJ; Afzal AS; Smith JA; Ford AP; Li JJ; Li Y; Kitt MM;
    Pulm Ther; 2021 Dec; 7(2):471-486. PubMed ID: 34152585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough.
    Muccino DR; Morice AH; Birring SS; Dicpinigaitis PV; Pavord ID; Assaid C; Kleijn HJ; Hussain A; La Rosa C; McGarvey L; Smith JA
    ERJ Open Res; 2020 Oct; 6(4):. PubMed ID: 33263037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant.
    Morice AH; Birring SS; Smith JA; McGarvey LP; Schelfhout J; Martin Nguyen A; Xu ZJ; Wu WC; Muccino DR; Sher MR
    Lung; 2021 Apr; 199(2):121-129. PubMed ID: 33825965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gefapixant in two randomised dose-escalation studies in chronic cough.
    Smith JA; Kitt MM; Butera P; Smith SA; Li Y; Xu ZJ; Holt K; Sen S; Sher MR; Ford AP
    Eur Respir J; 2020 Mar; 55(3):. PubMed ID: 31949115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomised trial of the P2X
    Niimi A; Saito J; Kamei T; Shinkai M; Ishihara H; Machida M; Miyazaki S
    Eur Respir J; 2022 Jun; 59(6):. PubMed ID: 34649978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2b Trial of P2X3 Receptor Antagonist Sivopixant for Refractory or Unexplained Chronic Cough.
    McGarvey L; Smith JA; Morice A; Birring SS; Chung KF; Dicpinigaitis PV; Niimi A; Benninger MS; Sher M; Matsunaga Y; Miyazaki S; Machida M; Ishihara H; Mahmood A; Gomez JC
    Lung; 2023 Feb; 201(1):25-35. PubMed ID: 36512069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of pharmacotherapy for refractory or unexplained chronic cough: a systematic review and network meta-analysis.
    Zheng Z; Huang J; Xiang Z; Wu T; Lan X; Xie S; Lin Z; Tang K; Morice A; Li S; Song WJ; Chen R
    EClinicalMedicine; 2023 Aug; 62():102100. PubMed ID: 37538538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Renal Impairment on the Pharmacokinetics of Gefapixant, a P2X3 Receptor Antagonist.
    Nussbaum JC; Hussain A; Min KC; Marbury TC; Lasseter K; Stoch SA; Iwamoto M
    J Clin Pharmacol; 2022 Nov; 62(11):1435-1444. PubMed ID: 35656754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study.
    Morice A; Smith JA; McGarvey L; Birring SS; Parker SM; Turner A; Hummel T; Gashaw I; Fels L; Klein S; Francke K; Friedrich C
    Eur Respir J; 2021 Nov; 58(5):. PubMed ID: 33986030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of gefapixant, a novel drug for the treatment of chronic cough: A systematic review and meta-analysis of randomized controlled trials.
    Abu-Zaid A; Aljaili AK; Althaqib A; Adem F; Alhalal DA; Almubarak AF; Aldughaither SM; Alghabban SA; Alfaraj G; Masoud AT; Alsuhaibani NA
    Ann Thorac Med; 2021; 16(2):127-140. PubMed ID: 34012479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.